advanced vaccine technology
PRRS – a highly evolved virus
Wild PRRS virus is well adapted to attach to and enter the pig’s
Pulmonary Alveolar Macrophages (PAMs) via the protein receptor CD163.
- Traditional attenuation uses a Green Monkey kidney cell line (MA104) which has a simian CD163 receptor.
- In the attenuation process the virus adapts to the simian CD163 receptor.
- When the attenuated virus is injected back into the pig it is not as well adapted to attach and enter the pig’s PAMs.
ONLY Suvaxyn® prrs mlv delivers a vaccine virus that can be administered from 1 day of age
Zoetis scientists discovered a new way to attenuate the PRRS virus.
- Zoetis scientists discovered a new way to attenuate the PRRS virus using a Baby Hamster kidney cell line engineered to express Porcine CD163.
- In the Zoetis attenuation process, the virus maintains a consistent natural fit to the porcine receptors.
- When the attenuated virus is injected back into the pig it maintains its ability to enter the pig’s PAMs.
- Zoetis Hypothesis: The Zoetis attenuation process leads to quick vaccine virus cell entry and rapid multiplication to provide high virus numbers to overcome MDAs.
no reversion to virulence seen in multiple passages in pigs1
Suvaxyn® prrs mlv - advanced virus technology
delivers a vaccine virus that:
- Maintains natural fit to Porcine CD163 receptor
- Has good cell entry
- Stimulates a strong immune response
- Overcomes MDAs – for much earlier administration
- No reversion to virulence seen in multiple passages in pigs1
the technology to deliver
administration from 1 day of age
Reference 1. Study Report No. B922N-ES-12-053, Zoetis Inc
